Literature DB >> 22559973

The molecular basis of adrenocortical cancer.

Tomasz Lehmann1, Tomasz Wrzesinski.   

Abstract

Adrenocortical tumors (ACTs) are common, and most are benign adrenocortical adenomas (ACAs). Malignant adrenocortical carcinoma (ACC) is a rare tumor type and is observed at the rate of one or two cases per million annually. ACTs are classified as either ACAs or ACCs by histopathologic methods that are based on nine Weiss scoring criteria, including the nuclear grade, mitotic rate, presence of necrosis, and others. In this review, we describe the findings of studies that have examined the molecular basis of ACTs, and we compare transcriptome analysis with other diagnostic approaches. ACTs are occasionally difficult to classify. Therefore, molecular techniques, such as microarray analysis, have recently been applied to overcome some of these diagnostic problems. We also discuss the likelihood of the diagnosis and discernment between ACAs and ACCs based on the molecular tests. To show the recent progress in understanding the etiology of ACTs, we highlight the relationship between genetic analysis and transcriptome analysis. We attempt to understand the role of abnormal cell growth and steroid hormone secretion. Genetic and transcriptome analyses have improved our understanding of ACTs considerably, yet many unanswered questions remain.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22559973     DOI: 10.1016/j.cancergen.2012.02.009

Source DB:  PubMed          Journal:  Cancer Genet


  12 in total

1.  Analysis of circulating microRNAs in adrenocortical tumors.

Authors:  Diana Rita Szabó; Michaela Luconi; Peter M Szabó; Miklós Tóth; Nikolette Szücs; János Horányi; Zoltán Nagy; Massimo Mannelli; Attila Patócs; Károly Rácz; Peter Igaz
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

2.  Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis.

Authors:  Timothy D Murtha; Reju Korah; Tobias Carling
Journal:  Surgery       Date:  2016-11-16       Impact factor: 3.982

3.  Ang-Tie Angiogenic Pathway Is Distinctively Expressed in Benign and Malignant Adrenocortical Tumors.

Authors:  Sofia Oliveira; Sofia S Pereira; Madalena M Costa; Mariana P Monteiro; Duarte Pignatelli
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

4.  MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.

Authors:  Dhaval Patel; Myriem Boufraqech; Meenu Jain; Lisa Zhang; Mei He; Krisana Gesuwan; Neelam Gulati; Naris Nilubol; Tito Fojo; Electron Kebebew
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

Review 5.  The 'omics' of adrenocortical tumours for personalized medicine.

Authors:  Guillaume Assié; Anne Jouinot; Jérôme Bertherat
Journal:  Nat Rev Endocrinol       Date:  2014-02-04       Impact factor: 43.330

6.  2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.

Authors:  Giada Poli; Elisabetta Ceni; Roberta Armignacco; Tonino Ercolino; Letizia Canu; Gianna Baroni; Gabriella Nesi; Andrea Galli; Massimo Mannelli; Michaela Luconi
Journal:  Oncotarget       Date:  2015-03-20

7.  Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence?

Authors:  Cristina L Ronchi; Silviu Sbiera; Ellen Leich; Katharina Henzel; Andreas Rosenwald; Bruno Allolio; Martin Fassnacht
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

8.  The effects of mitotane and 1α,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells.

Authors:  B Rubin; C Pilon; R Pezzani; A Rebellato; F Fallo
Journal:  J Endocrinol Invest       Date:  2019-10-05       Impact factor: 4.256

9.  Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.

Authors:  Reju Korah; James M Healy; John W Kunstman; Annabelle L Fonseca; Amir H Ameri; Manju L Prasad; Tobias Carling
Journal:  Mol Cancer       Date:  2013-08-05       Impact factor: 27.401

10.  Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.

Authors:  J S Ross; K Wang; J V Rand; L Gay; M J Presta; C E Sheehan; S M Ali; J A Elvin; E Labrecque; C Hiemstra; J Buell; G A Otto; R Yelensky; D Lipson; D Morosini; J Chmielecki; V A Miller; P J Stephens
Journal:  J Clin Pathol       Date:  2014-07-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.